Evidence map›Paper›PMID 35371915›Full record

ArticleLeukemia research reports2022

Emergence of t(3;21)(q26.2;q22) during eltrombopag treatment in a patient with relapsed aplastic anemia who received chemotherapy for angioimmunoblastic T-cell lymphoma.

Fumi Nakamura, Yuka Nakamura, Yasuhito Nannya, Honoka Arai, Kei Shimbo, Yuko Nakamura, Sachiko Seo, Ko Sasaki, Motoshi Ichikawa, Seishi Ogawa and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fumi NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Yuka NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Honoka AraiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Kei ShimboClinical Laboratory Center, Dokkyo Medical University Hospital, Tochigi, Japan.
Yuko NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Ko SasakiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Motoshi IchikawaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, 321-0293, Japan.
Dokkyo Medical University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 65-year-old man with nonsevere aplastic anemia received rabbit anti-thymocyte globulin and cyclosporine and partially responded. Six months after the initiation of treatment, he was diagnosed with stage IV angioimmunoblastic T-cell lymphoma and received chemotherapy. PET/CT scan analysis indicated a complete response. However, he showed sustained myelosuppression and was diagnosed with relapse of aplastic anemia. He did not respond to cyclosporine, eltrombopag or methenolone. Fifteen months after eltrombopag administration, he developed MDS with t(3;21)(q26.2;q22). Patients should be monitored carefully for the emergence of not only -7/del(7q) but also 3q26 abnormalities, including t(3;21)(q26.2;q22), during and after eltrombopag treatment.

Indexed as

3q26 abnormalitiesAngioimmunoblastic t-cell lymphomaAplastic anemiaEltrombopagMyelodysplastic syndromes

Identifiers

PMID35371915
PMCPMC8966168
OpenAlexW4220918201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.